Invention Grant
- Patent Title: Anticancer agent and side-effect-alleviating agent
-
Application No.: US15302863Application Date: 2015-04-10
-
Publication No.: US09907852B2Publication Date: 2018-03-06
- Inventor: Hiroyasu Esumi , Masafumi Ikeda , Katsuya Tsuchihara , Shigeki Chiba , Satoshi Yomoda , Takanori Kawashima , Toshiki Okubo , Yasuhiro Tezuka , Kenta Murata
- Applicant: National University Corporation University of Toyama , Kracie Pharma, Ltd. , National Cancer Center , Tokyo University of Science Foundation
- Applicant Address: JP Toyama JP Tokyo JP Tokyo JP Tokyo
- Assignee: National University Corporation University of Toyama,Kracie Pharma, Ltd.,National Cancer Center,Tokyo University of Science Foundation
- Current Assignee: National University Corporation University of Toyama,Kracie Pharma, Ltd.,National Cancer Center,Tokyo University of Science Foundation
- Current Assignee Address: JP Toyama JP Tokyo JP Tokyo JP Tokyo
- Agency: Sunstein Kann Murphy & Timbers LLP
- Priority: JP2014-080895 20140410
- International Application: PCT/JP2015/061296 WO 20150410
- International Announcement: WO2015/156409 WO 20151015
- Main IPC: A61K31/34
- IPC: A61K31/34 ; A61K36/00 ; A61K47/22 ; A61K36/28 ; A61K31/7068 ; A61K45/06 ; A61K47/46 ; A61K39/395 ; C07K16/22 ; A61K39/00

Abstract:
The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.
Public/Granted literature
- US20170028065A1 ANTICANCER AGENT AND SIDE-EFFECT-ALLEVIATING AGENT Public/Granted day:2017-02-02
Information query